Business Description
Rigel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7665596034
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.94 | |||||
Equity-to-Asset | -0.24 | |||||
Debt-to-Equity | -2.12 | |||||
Debt-to-EBITDA | -3.57 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -14.99 | |||||
Beneish M-Score | -3.46 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.4 | |||||
3-Year EBITDA Growth Rate | 15.8 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 27.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 24.94 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.03 | |||||
9-Day RSI | 56.3 | |||||
14-Day RSI | 49.33 | |||||
6-1 Month Momentum % | 51.83 | |||||
12-1 Month Momentum % | 17.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.76 | |||||
Cash Ratio | 1.07 | |||||
Days Inventory | 437.5 | |||||
Days Sales Outstanding | 90.31 | |||||
Days Payable | 504.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -10.05 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.92 | |||||
Operating Margin % | -17.53 | |||||
Net Margin % | -21.47 | |||||
FCF Margin % | -17.85 | |||||
ROA % | -20.65 | |||||
ROIC % | -42.22 | |||||
ROC (Joel Greenblatt) % | -837.19 | |||||
ROCE % | -25.94 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.79 | |||||
EV-to-EBIT | -11.75 | |||||
EV-to-Forward-EBIT | -13.81 | |||||
EV-to-EBITDA | -12.61 | |||||
EV-to-Forward-EBITDA | -13.81 | |||||
EV-to-Revenue | 1.83 | |||||
EV-to-Forward-Revenue | 1.52 | |||||
EV-to-FCF | -10.32 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Earnings Yield (Greenblatt) % | -8.51 | |||||
FCF Yield % | -9.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Rigel Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 108.348 | ||
EPS (TTM) (€) | -0.131 | ||
Beta | 1.31 | ||
Volatility % | 81.61 | ||
14-Day RSI | 49.33 | ||
14-Day ATR (€) | 0.040792 | ||
20-Day SMA (€) | 1.052925 | ||
12-1 Month Momentum % | 17.17 | ||
52-Week Range (€) | 0.6678 - 1.6345 | ||
Shares Outstanding (Mil) | 175.4 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Rigel Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Rigel Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Rigel Pharmaceuticals Inc Frequently Asked Questions
What is Rigel Pharmaceuticals Inc(STU:RI2A)'s stock price today?
When is next earnings date of Rigel Pharmaceuticals Inc(STU:RI2A)?
Does Rigel Pharmaceuticals Inc(STU:RI2A) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |